|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's range||134.74 - 137.51|
|52-week range||105.43 - 183.00|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BOTHELL, Wash., January 19, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA’s Accelerated Approval Program based on tum
BOTHELL, Wash., January 19, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
BOTHELL, Wash., December 20, 2022--Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com.